News
-
Acorda Therapeutics has announced that Chief Technology Officer Rick Batycky is leaving the company as of August 20, 2018 to head up a new private biotech firm. Batycky co-founded Civitas Therapeutics, which was acquired by… Read more . . .
-
US-based Onspira Therapeutics has announced that its OSP-101, an inhaled interleukin-1 receptor antagonist (IL-1Ra) for the treatment of bronchiolitis obliterans, has been granted orphan drug designation by the FDA. Onspira is a private company created… Read more . . .
-
Haisco Pharmaceutical Group has acquired Chinese rights to products developed by Pneuma Respiratory in a deal that included a $10 million equity investment in Pneuma, the company said. In addition to the equity investment, Haisco… Read more . . .
-
UCB announced that the FDA has accepted its new drug application for USL261 midazolam nasal spray for the rescue treatment of seizures in epilepsy patients. The company announced in April 2018 that it had acquired… Read more . . .
-
Proveris Scientific Corporation has announced the appointment of John Masciola as VP of Product Development. Masciola was most recently Engineering Manager at Parker Precision Fluidics, and his experience in the life sciences industry includes positions… Read more . . .
-
Perrigo has licensed the US rights to an over-the-counter version of Merck’s Nasonex mometasone furoate nasal spray, the company said. The company did not disclose the financial terms of the deal, which give Perrigo the… Read more . . .
-
United Therapeutics has announced a settlement agreement with Watson Laboratories that includes a license for Watson to manufacture and sell a generic version of Tyvaso treprostinil inhalation solution as of January 1, 2026. Watson is… Read more . . .
-
Florida-based Product Quest Manufacturing has recalled a lot of CVS Health 12 Hour Sinus Relief Nasal Mist oxymetazoline nasal spray due to contamination with Pseudomonas aeruginosa. The company said that it had not received reports… Read more . . .
-
Milestone Pharmaceuticals said that it has initiated a Phase 3 clinical study of etripamil, an intranasal calcium channel antagonist for the treatment of paroxysmal supraventricular tachycardia (PSVT). Results from a Phase 2 study of etripamil… Read more . . .
-
Eurocine Vaccines said that results from a study of its Immunose Flu intranasal flu vaccine in adults aged 50-70 showed no serious adverse events and only minimal experiences of discomfort. The study, which took place… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.